Congenital heart disease has a genetic component, but it’s rarely caused by genetics alone. About 35% of cases can be traced to a known genetic cause, while roughly 10% are linked to environmental factors like maternal health conditions. The remaining 55% have no identified cause, likely resulting from complex interactions between multiple genes and environmental exposures. Affecting approximately 1% of all live births worldwide, congenital heart disease is one of the most common birth defects, and understanding what drives it matters for both parents and patients.
How Genetics Contribute to CHD
Genetic causes of congenital heart disease fall into three broad categories: chromosomal abnormalities (where large chunks of genetic material are missing, duplicated, or rearranged), single-gene mutations (where one specific gene is altered), and polygenic effects (where many small genetic variations add up to increase risk). Only about a third of the estimated genes that cause congenital heart disease have been confirmed so far, which is a big part of why so many cases remain unexplained.
Chromosomal conditions are among the most well-recognized genetic causes. Down syndrome, caused by an extra copy of chromosome 21, leads to heart defects in 40 to 50% of affected children. The most common defects in Down syndrome involve holes between the heart’s chambers and problems with the valves that separate the upper and lower chambers.
Another major genetic cause is 22q11.2 deletion syndrome (sometimes called DiGeorge syndrome), where a small piece of chromosome 22 is missing. Between 60 and 80% of people with this deletion have some form of heart malformation. The most common is tetralogy of Fallot, a combination of four structural problems that affects the heart’s ability to pump oxygen-rich blood to the body. This defect appears in about half of all people diagnosed with 22q11.2 deletion syndrome.
Single-Gene Mutations and Heart Development
Several individual genes play critical roles in building the heart during fetal development. Three of the best-studied are genes involved in forming the walls (septa) that divide the heart’s chambers. Mutations in one of these genes account for at least 4% of tetralogy of Fallot cases. Another gene has been linked to holes between the heart’s upper chambers (atrial septal defects), holes between the lower chambers (ventricular septal defects), and tetralogy of Fallot. A third gene, when mutated, causes Holt-Oram syndrome, which affects both the heart and the skeleton, typically causing abnormalities in the hands or arms alongside septal defects.
These three genes appear to work together as a team, regulating the development of the heart’s internal walls. When any one of them is disrupted, the result can range from a small hole that closes on its own to a complex defect requiring surgery. This variability is part of what makes genetic heart disease so unpredictable, even within the same family carrying the same mutation.
Environmental Factors That Raise Risk
Genetics is only part of the picture. Maternal health during pregnancy plays a measurable role, particularly diabetes. Mothers with diabetes that existed before pregnancy face a 4.3-fold higher risk of having a baby with a critical congenital heart defect. Diabetes that develops during pregnancy (gestational diabetes) carries a smaller but still significant 1.47-fold increased risk. High blood sugar during the first trimester, when the heart is forming, is thought to disrupt normal cardiac development.
Other maternal factors linked to increased risk include high blood pressure before pregnancy (1.34-fold increased risk), high blood pressure during pregnancy (1.16-fold), and smoking during pregnancy (1.18-fold). Higher maternal BMI and late entry into prenatal care are also associated with greater risk. These numbers may seem modest individually, but they underscore that some portion of congenital heart disease risk is modifiable.
One of the most actionable findings in CHD prevention involves folic acid. Taking folic acid supplements around the time of conception is associated with roughly a 28% reduction in congenital heart disease risk. One Chinese study found that using folic acid-containing multivitamins for three or more months before pregnancy was associated with a 69% risk reduction, though results vary across populations and study designs.
Recurrence Risk for Families
If you or your partner has a congenital heart defect, or if you’ve had a child with one, the risk of it happening again is higher than the general population’s 1% rate, but still relatively low in most cases. When one previous child was affected, the recurrence rate for a future sibling is about 3.5%. When the mother herself has a congenital heart defect, the risk to her child is approximately 5.2%. Interestingly, when the father is the one affected, the recurrence rate is slightly higher at 7.5%, though some studies have found the opposite pattern.
Recurrence risk also depends on the specific defect. For common defects like ventricular septal defects (holes in the wall between the lower chambers), sibling recurrence is under 2%. For rarer or more complex defects, the numbers can be higher. Overall, the accepted model is that most congenital heart disease follows a “multifactorial” inheritance pattern, meaning it takes a combination of genetic susceptibility and environmental triggers rather than a single inherited gene.
Genetic Testing During Pregnancy
When a heart defect is detected on a prenatal ultrasound, genetic testing is typically the next step. The current first-line test is chromosomal microarray analysis, which scans for missing or extra pieces of DNA across all chromosomes. Combined with standard chromosome analysis and targeted tests, this approach identifies a genetic cause in roughly 30 to 40% of cases.
For cases where microarray comes back normal, whole exome sequencing (which reads essentially all protein-coding genes) can sometimes find the answer. This more comprehensive test picks up an additional 8 to 17% of diagnoses, with higher success rates when the heart defect occurs alongside other physical abnormalities (10 to 50% diagnostic yield) compared to isolated heart defects (7 to 28%). However, exome sequencing also frequently turns up genetic changes of uncertain meaning, which can make results harder to interpret. For this reason, it is not yet a routine clinical test and is more commonly used in research settings.
Why So Many Cases Remain Unexplained
The fact that over half of congenital heart disease cases have no identified cause reflects the complexity of heart development. The heart is the first organ to form in an embryo, and its construction requires thousands of genes working in precise coordination over just a few weeks. Researchers are increasingly finding that many cases likely result from the combined effect of dozens or even hundreds of common genetic variants, each contributing a tiny amount of risk. Early work on polygenic risk scores, which add up these small effects, has shown some ability to distinguish people with congenital heart disease from those without, but the scores currently explain only about 2.5% of the variation in who develops the condition. That’s a long way from being useful for individual prediction.
The interplay between genes and environment adds another layer. A fetus might carry a genetic susceptibility that only leads to a heart defect when combined with a specific environmental exposure during a critical window of development. This gene-environment interaction is widely suspected but difficult to prove in individual cases, which is why so many families never receive a definitive answer about what caused their child’s heart defect.